Nyxoah (NASDAQ:NYXH) versus Decision Diagnostics (OTCMKTS:DECN) Financial Survey

Nyxoah (NASDAQ:NYXH) and Decision Diagnostics (OTCMKTS:DECN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Profitability

This table compares Nyxoah and Decision Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-1,541.84%	-79.18%	-54.92%
Decision Diagnostics	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and price targets for Nyxoah and Decision Diagnostics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1	0	3	0	2.50
Decision Diagnostics	0	0	0	0	0.00

Nyxoah presently has a consensus target price of $15.00, suggesting a potential upside of 146.31%. Given Nyxoah’s stronger consensus rating and higher possible upside, analysts clearly believe Nyxoah is more favorable than Decision Diagnostics.

Earnings & Valuation

This table compares Nyxoah and Decision Diagnostics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$4.89 million	42.42	-$64.10 million	($2.30)	-2.65
Decision Diagnostics	N/A	N/A	N/A	N/A	N/A

Decision Diagnostics has lower revenue, but higher earnings than Nyxoah.

Volatility and Risk

Nyxoah has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Decision Diagnostics has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500.

Summary

Nyxoah beats Decision Diagnostics on 5 of the 8 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About Decision Diagnostics

Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.